title: Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.
abstract: Targeted therapies have improved survival in patients with metastatic renal cell cancer (RCC); however, expert opinion on the optimal therapeutic strategy is divided. This retrospective study evaluates different sequential schemes of targeted therapies in 310 patients with advanced/metastatic RCC who received different systemic agents - sorafenib, sunitinib, bevacizumab, everolimus, temsirolimus and axitinib - alone or in different sequences, until disease progression or intolerable toxicity (median follow-up: 37 months). The median overall survival (OS) was 22 months and the 5-year OS was 23.4%; differential therapeutic schemes were not associated with differences in OS. A worse performance status, no nephrectomy and a poor-risk classification according to the Motzer criteria was associated with a shorter OS. These findings support the use of targeted therapies in the treatment of RCC, even in a large unselected population from a single institution, and suggest that treatment should be tailored to meet individual circumstances and needs.
authors: Fondazione IRCCS Istituto Nazionale Tumori, Medical Oncology, Via G. Venezian 1, 20133 Milan, Italy. giuseppe.procopio@istitutotumori.mi.it
authors: Giuseppe
authors: G
authors: Procopio
authors: Elena
authors: E
authors: Verzoni
authors: Roberto
authors: R
authors: Iacovelli
authors: Valentina
authors: V
authors: Guadalupi
authors: Francesco
authors: F
authors: Gelsomino
authors: Roberto
authors: R
authors: Buzzoni
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000379:methods; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents